C. albicans and C. glabrata are ubiquitous in the environment and commensal inhabitants of the normal flora of the oral cavity, gastrointestinal tract and skin of most healthy humans.^1,2 For the immunocompromised, however, C. albicans and C. glabrata are the two most commonly recovered pathogenic yeasts in the United States and together are responsible for approximately 70% of all cases of systemic candidiasis, with increasing occurrences of multidrug resistance.^1-4

BEI Resources houses over 50 strains of Candida spp. to support candidiasis research. Recent additions to our catalog include an azole-susceptible strain of C. glabrata (NR-51685) and an azole-resistant C. glabrata strain isolated from the same patient after 50-day azole therapy (NR-51686).⁴ Also newly available is a transgenic strain of C. albicans (NR-51634) that constitutively expresses green fluorescent protein (GFP) and red fluorescent protein via mCherry, which has been used as an in vitro system for fluorescent sorting of C. albicans with macrophages.¹

For more information about these and other Candida strains available from BEI Resources, or to contribute to our expanding catalog of biomaterials for fungal research, please contact us at Contact@BEIResources.org.

References:

1. Muñoz, J. F., et al. “Coordinated Host-Pathogen Transcriptional Dynamics Revealed Using Sorted Subpopulations and Single Macrophages Infected with Candida albicans.” Nat. Commun. 10 (2019): 1607. PubMed: 30962448.
2. Brunke, S. and B. Hube. “Two Unlike Cousins: Candida albicans and C. glabrata Infection Strategies.” Cell. Microbiol. 15 (2013): 701-708. PubMed: 23253282.
3. Hendrickson, J. A., et al. “Antifungal Resistance: A Concerning Trend for the Present and Future.” Curr. Infect. Dis. Rep. 21 (2019): 47. PubMed: 31734730.
4. Vale-Silva, L., et al. “Comparative Genomics of Two Sequential Candida glabrata Clinical Isolates.” G3 (Bethesda) 7 (2017): 2413-2426. PubMed: 28663342.

Image:  Fluorescence microscopy of transgenic Candida albicans, NR-51634 (BEI Resources)

Infections with multidrug-resistant Pseudomonas aeruginosa, one of the most common healthcare-associated infections among immunocompromised and post-surgery patients, affected an estimated 32,600 patients in the United States in 2017, resulting in nearly 3,000 deaths, and is the predominant pathogen causing lung infections in individuals with cystic fibrosis and other pulmonary disorders.^1-3 Rising rates of multidrug-resistant isolates of P. aeruginosa limit treatment options, strengthening the need for new antimicrobials and alternative tools. A new collection of P. aeruginosa strains, selected from a respository of over 3,400 clinical isolates collected worldwide between 2003 and 2017, is now available to the research community focusing on multidrug-resistant P. aeruginosa.

This unique panel of 100 highly diverse, multidrug-resistant P. aeruginosa strains from the Multidrug Resistant Organism Repository and Surveillance Network (MRSN) within Walter Reed Army Institute of Research's Bacterial Diseases Branch represents isolates from each phylogenetic group with a wide-range of well-characterized antibiotic resistance patterns. Extensive data is available for each isolate, including isolation history, whole genome sequencing, characterization by mutilocus sequence typing, a comprehensive list of antibiotic resistance genes carried, and antibiotic susceptibilities to eleven clinically relevant antibiotics commonly used to treat P. aeruginosa infections: amikacin, aztreonam, ceftazidime, ciprofloxacin, cefepime, gentamicin, imipenem, levofloxacin, meropenem, tobramycin and piperacillin/tazobactam.

The P. aeruginosa MRSN Diversity Panel is available as both a complete kit containing all 100 strains as BEI Resources NR-51829, as well as individually.

References:

1. “Multidrug-resistant Pseudomonas aeruginosa.” Centers for Disease Control and Prevention, U. S. Department of Health and Human Services, https://www.cdc.gov/drugresistance/pdf/threats-report/pseudomonas-aeruginosa-508.pdf.
2. Cabot, G., et al. “Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.” Antimicrob. Agents Chemother. 60 (2016): 1767-1778. PubMed: 26729493.
3. Pang, Z., et al. “Antibiotic Resistance in Pseudomonas aeruginosa: Mechanisms and Alternative Therapeutic Strategies.” Biotechnol. Adv. 37 (2019): 177-192. PubMed: 30500353.

Image:  Illustration of multidrug-resistant Pseudomonas aeruginosa (CDC/Medical Illustrator: Jennifer Oosthuizen)

Acanthamoeba spp., Balamuthia mandrillaris and Naegleria fowleri are free-living amoebae inhabiting a wide variety of environmental niches worldwide, with the potential to cause infections in both humans and animals.

Acanthamoeba spp. and B. mandrillaris are opportunistic pathogens of the central nervous system, lungs, sinuses and skin, primarily in immunocompromised patients and, in severe cases, lead to the fatal disease granulomatous amebic encephalitis.^1-3 Among individuals wearing contact lenses, Acanthamoeba spp. is the causative agent of the sight-threatening infection Acanthamoeba keratitis.³ In contrast, N. fowleri, commonly known as the “brain-eating amoeba”, is pathogenic in healthy humans, causing acute and fulminant primary amoebic meningoencephalitis, a water-borne disease of the central nervous system resulting in extensive tissue damage, inflammation and hemorrhagic necrosis.⁴ Infection with N. fowleri is primarily associated with recreational activities in freshwater lakes and reservoirs naturally heated by the sun, as well as in geothermal sources and water thermally polluted by industry.^3,4

The availability of clinical isolates is essential for the advancement of research into the biology, mechanisms of pathogenesis, immunology, antimicrobial susceptibility and molecular characteristics of these amoebae. BEI Resources maintains a collection of free-living amoeba, currently totaling 50 isolates, deposited by the Free-Living & Intestinal Amebas Laboratory, Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention. Each isolate is cataloged with the geographical location, year and source of isolation and reported genotype. Please visit the BEI Resources website for a complete list of isolates in our free-living amoeba catalog.

References:

1. Marciano-Cabral, F. and G. Cabral. ”Acanthamoeba spp. as Agents of Disease in Humans.” Clin. Microbiol. Rev. 16 (2003): 273-307. PubMed: 12692099.
2. Cope, J. R., et al. “The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974-2016.” Clin. Infect. Dis. 68 (2019): 1815-1822. PubMed: 30239654.
3. Visvesvara, G. S. “Amebic Meningoencephalitides and Keratitis: Challenges in Diagnosis and Treatment.” Curr. Opin. Infect. Dis. 23 (2010): 590-594. PubMed: 20802332.
4. Siddiqui, R., et al. “Biology and Pathogenesis of Naegleria fowleri.” Acta Trop. 164 (2016): 375-394. PubMed: 27616699.

Image:  Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri (BEI Resources)

Multidrug-resistant (MDR) isolates of S. enterica subsp. enterica serovar Typhi (S. typhi), the causative agent of typhoid fever, prevalent in parts of Asia and Africa are often associated with the dominant H58 haplotype, which harbors an IncHI1 plasmid with multiple resistance genes to first-line drugs, including ^blaTEM-1 (ampicillin), catA1 (chloramphenicol), dfrA7, sul1, sul2 (sulfamethoxazole/trimethoprim) and strAB (streptomycin) resistance genes.¹

The recent emergence of a novel, extensively drug-resistant (XDR) S. typhi H58 clone with additional resistance to fluoroquinolones and third-generation cephalosporins has been reported in Sindh, Pakistan.^1,2 This XDR clone encodes a chromosomally located resistance region and harbors the antibiotic resistance-associated IncY plasmid p60006, specific to XDR isolates in this phylogenetic branch.¹ This plasmid encodes additional elements, including the extended-spectrum beta-lactamase (^blaCTX-M-15) and fluoroquinolone (qnrS) resistance genes, and exhibited high sequence identity to plasmids found in other enteric bacteria, particularly Escherichia coli, isolated from widely distributed geographic locations.¹

Five strains of this XDR S. typhi clone from the Pakistan outbreak have been recently added to the BEI Resources catalog, expanding our collection of bacteria with unique resistance profiles to support antimicrobial resistance research:

References:

1. Klemm, E. J., et al. “Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins.” MBio 9 (2018): e00105-18. PubMed: 29463654.
2. Chatham-Stephens, K., et al. “Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.” MMWR Morb. Mortal. Wkly. Rep. 68 (2019): 11- 13. PubMed: 30629573.

Image:  Computer-generated image of Salmonella serotype Typhi bacteria (CDC/Medical Illustrator)

Usutu Virus (USUV) is an emerging mosquito-borne flavivirus belonging to the Japanese encephalitis virus serocomplex, with a similar transmission cycle as West Nile virus.^2,3 USUV is maintained in the environment through an enzootic cycle between several bird and mosquito species, with humans and mammals as the incidental dead-end hosts.^2,3

First isolated in 1959 from Culex neavei mosquitos in South Africa, and named after the nearby Usutu River, USUV has spread from southern Africa to Europe by way of migratory birds, thought to be the major amplifying host, where it has caused significant avian outbreaks and infections in humans and horses.^1-3 Infections in humans, while low, range from mild and asymptomatic to serious neuroinvasive diseases like encephalitis and meningoencephalitis. Co-circulation with West Nile virus, confirmed in numerous European countries in mosquito, bird and horse species, and positive serology for both viruses reported in both birds and humans, raises epidemiological issues, furthering the need for research and diagnostic tools to address USUV as a potential human pathogen in the future.^2-4

BEI Resources supports this continuing research by offering two Usutu virus isolates available in the BEI Resources catalog: ENT MP 1626 (NR-51185), isolated in 1962 from Mansonia aurites mosquitoes in Zika Forest, Uganda, and the prototype African strain SAAR 1776 (NR-51184), the first isolation of the virus in 1959 from Culex neavei mosquitos in South Africa.

References:

1. McIntosh, B. M. “Usutu (SAAr 1776); Nouvel Arbovirus du Groupe B.” Int. Cat. Arboviruses 3 (1985): 367- 374.
2. Clé, M., et al. “Usutu Virus: A New Threat?” Epidemiol. Infect. 147 (2019): e232. PubMed: 31364580.
3. Roesch, F., et al. “Usutu Virus: An Arbovirus on the Rise.” Viruses 11 (2019): E640. PubMed: 31336826.
4. Nikolay, B. “A Review of West Nile and Usutu Virus Co-Circulation in Europe: How Much Do Transmission Cycles Overlap?” Trans. R. Soc. Trop. Med. Hyg. 109 (2015): 609-618. PubMed: 26286946.

Image:  Larvae of Culex Mosquitoes (CDC/James Gathany)

The “Asian Longhorned Tick”, Haemaphysalis longicornis, is invasive in the United States, first identified in New Jersey in 2017, and is rapidly spreading. While human pathogens have not yet been identified within H. longicornis found within the United States, the vector is known to be competent for transmission of a number of zoonotic tick-borne disease pathogens, including Borrelia, Rickettsia, Erlichia and Anaplasma species, Powassan virus and several Babesia parasites.^1-4 In China, H. longicornis is a vector of the severe fever with thrombocytopenia syndrome (SFTS) virus, an emerging phlebovirus with high mortality rates.⁵

H. longicornis is especially of agricultural concern with cattle and sheep, transmitting tropical theileriosis, a potentially fatal parasitic infection in cattle in southern Europe, Africa and Asia. In sheep, H. longicornis infestation impacts both the quality and quantity of wool. This disease host is known to be difficult to control and is unique among ticks in the ability of the females to reproduce by parthenogenesis (full development of unfertilized eggs), as well as by sexual reproduction.

As of August 1, 2019, Asian longhorned ticks have spread to nearly one quarter of the United States, affecting Arkansas, Connecticut, Delaware, Kentucky, Maryland, North Carolina, New Jersey, New York, Pennsylvania, Tennessee, Virginia and West Virginia.⁶

The newly available H. longicornis colony established from a wild-type, parthenogenic strain deposited by Dr. Michael Levin, Centers for Disease Control and Prevention, is confirmed specific-pathogen-free (SPF) by molecular screening and is available to qualified insectaries in the larval, nymph and adult life stages:

References:

1. Lee, M.-J. and Joon-Seok Chae. “Molecular Detection of Erhlichia chaffeensis and Anaplasma bovis in the Salivary Glands from Haemaphysalis longicornis Ticks.” Vector Borne Zoonotic Dis. 10 (2010): 411-413. PubMed: 19874189.
2. Meng, Z., et al. “[Detection of Co-Infection with Lyme Spirochetes and Spotted Fever Group Rickettsiae in a Group of Haemaphysalis longicornis].” Zhonghua Liu Xing Bing Xue Za Zhi [Chinese Journal of Epidemiology] 29 (2008): 1217-1220. PubMed: 19173967.
3. Hoogstraal, H. “Changing Patterns of Tickborne Diseases in Modern Society.” Annu. Rev. Entomol. 26 (1981): 75-99. PubMed: 7023373.
4. Heath, A. C. G. “Vector Competence of Haemaphysalis longicornis with Particular Reference to Blood Parasites.” Surveillance 29 (2002): 12-14. http://www.sciquest.org.nz/node/47255.
5. Yu, X. J., et al. “Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China.” N. Engl. J. Med. 364 (2011): 1523-1532. PubMed: 21410387.
6. “What You Need to Know About Asian Longhorned Ticks - A New Tick in the United States.” Centers for Disease Control and Prevention, U. S. Department of Health and Human Services, //www.cdc.gov/ticks/longhorned-tick/index.html.

Image:  Adult female Haemaphysalis longicornis tick (CDC/James Gathany)

BEI Resources continues to expand the catalog of luciferase-expressing parasitic protists. Recent additions include Leishmania mexicana, strain MNYC/BZ/62/M379 transfected with the luciferase gene from the sea pansy Renilla reniformis (NR-51210) and Trypanosoma cruzi, strain CL Brener expressing the thermostable red-shifted luciferase gene mutant, PpyRE9 (NR-49161). These models allow the high-throughput screening of large numbers of candidate compounds during infection in vitro and the possibility of tracking parasite distribution in vivo in laboratory mice. The expression of red-shifted luciferase in T. cruzi, in particular, results in a reporter system that is more sensitive than other bioluminescence systems previously reported. The availability of these new transgenic strains provides the researcher rapid quantification of parasite growth and simplification of the methodology for scoring inhibitor assays.

Reference:

Lewis, M.D., et al. “A New Experimental Model for Assessing Drug Efficacy Against Trypanosoma cruzi Infection Based on Highly Sensitive in vivo Imaging.” J. Biomol. Screen. 20 (2015): 36-43. PubMed: 25296657.

Image:  Trypanosoma cruzi CL Brener PpyRE9 (NR-49161) epimastigotes stained with GIEMSA (BEI Resources)

Now available are two well-characterized reference reagents for Zika virus (ZIKV) to facilitate evaluation of existing nucleic acid testing (NAT) assays and development of novel ZIKV assays. These reagents were produced by The Center for Biologics Evaluation and Research/U.S. Food and Drug Administration (CBER/FDA) from heat-inactivated (HI) ZIKV culture supernatant stock from two strains, PRVABC59 and FSS13025, which were diluted in dialyzed, defibrinated human plasma, and lyophilized. These reagents add to the expansive catalog of Zika virus materials now available from BEI Resources.

Image:  Female Aedes aegypti mosquito (CDC/James Gathany)

Coccidioidomycosis, also known as Valley fever, is an invasive fungal infection caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. These fungi are endemic to arid or semi-arid regions of the southwestern United Sates, Mexico, and Central and South America. Infection is acquired through inhalation of air-dispersed fungal spores termed arthroconidia. The initial or acute form of coccidioidomycosis is often mild with symptoms such as fever, cough, chest pain, and red, spotty rash. If infection is not controlled, it may progress to chronic pneumonia or even disseminate to other parts of the body including the brain, especially in immunocompromised patients. BEI Resources houses a well-characterized collection of Coccidioides strains from various origins, which have been used in studies of the ecology and distribution of different genotypes of the pathogen. Such studies are important for monitoring outbreaks, determining changes in virulence, and predicting disease progression. These strains were generously contributed by Dr. Bridget Barker, Northern Arizona University.

Image:  Colonies of Coccidioides immitis, Strain RMSCC 3476 (NR-48939) growing at 37°C on Emmons' Modification of Sabouraud agar.

Burkholderia pseudomallei, the causative agent for melliodiosis, is an opportunistic pathogen found in soil in tropic and subtropic regions worldwide.  B. pseudomallei is classified as a category B, Tier 1 Select Agent in the United States due to a high mortality rate when untreated, and the potential for its use as a biowarfare agent through aerosol transmission. Most strains of B. pseudomallei require handling under Biosafety level 3 (BSL 3). B. pseudomallei, strain Bp82 (deltapurM) has a 109 base pair deletion within the purM open reading frame, rendering the strain avirulent in mouse and hamster models.  B. pseudomallei, strain Bp82 (deltapurM) is now an Excluded Strain from the HHS and USDA Select Agents and Toxins ­Exclusions list and can be handled under BSL 2 conditions. Strain Bp82 (deltapurM) has been proposed as a vaccine candidate and has been used in antibiotic resistance studies.  This strain was graciously deposited into BEI Resources by Dr. Herbert Schweizer, and is available as item number NR-51280.

Reference:

Propst, K. L., et al. “A Burkholderia pseudomallei deltapurM Mutant is Avirulent in Immunocompetent and Immunodeficient Animals: Candidate Strain for Exclusion from Select-Agent Lists.” Infect. Immun. 78 (2010): 3136-3143. PubMed: 20404077.

Image:  Burkholderia pseudomallei culture on sheep blood agar (CDC/ Larry Stauffer)

Enterovirus and Acute Flaccid Myelitis Research Materials

In support of Enterovirus-D68 (EV-D68) vaccine development research, BEI Resources has performed initial screening of cell lines amenable for human vaccine development. The following study assesses the suitability of cell lines for virus propagation in the presence of serum and after adaptation to serum free (SF) conditions. A guidance on how to adapt cell lines to serum free media is provided.

Enterovirus and Acute Flaccid Myelitis
Enterovirus D68 (EV-D68) has reemerged as a cause of severe respiratory infections in young children around the world and as a newly emerged neuropathogenic threat. First isolated in the United States (US) from children with serious respiratory illness in 1962¹, only sporadic clusters of EV-D68 infection were reported globally in the last decade² until 2014 when an unusually large outbreak occurred in the US. During this outbreak (and in subsequent 2016 and 2018 outbreaks), a subset of children with laboratory confirmed EV-D68 related severe respiratory illness also developed an acute flaccid myelitis (AFM). Detection of virus in the spinal fluid of AFM affected children³ is rare but recently, researchers have found new evidence linking AFM to enteroviruses due to the presence of higher levels of EV specific antibodies in cerebrospinal fluid of children with AFM compared to non-AFM controls^4,5.

BEI Resources Screening of Cell Lines for EV-D68 Propagation in Media Supplemented with Serum
Typically, EV-D68 is propagated in human rhabdomyosarcoma (RD) cells (ATCC^® CCL-136™) at 33°C. However, this cell line is not amenable for vaccine production and additionally is maintained in serum containing media. Consequently, BEI Resources has performed an initial screen of suitable cell substrates for EV-D68 vaccine development. Five cell lines were tested for EV-D68 susceptibility and production rates to assess the successful propagation using two EV-D68 isolates originally grown in RD cells that are available in BEI Resources (see Table 1 for details).

Prior to infection, the cell lines were maintained at 37°C. Viral growth media contained 2% fetal bovine serum (FBS) (ATCC^® 30-2020™) and the ATCC^® recommended base media for each cell line (Table 1). The cells were infected with each viral strain using a multiplicity of infection (MOI) of 0.01 and incubated at 33°C. When approximately 90% of the cells showed cytopathic effect (CPE), the virus was harvested by scraping the monolayer into the supernatant. The infected cell lysate was clarified by centrifugation at 2400g and the pellet underwent three freeze-thaw cycles to release the virus which was then added back to the supernatant. The viruses were titrated in RD cells by the 50% Tissue Culture Infectious Dose (TCID₅₀) method and calculated by the Reed-Muench method. If a virus infected cell line displayed no signs of CPE after an extended incubation period of 12-14 days, the absence of virus was confirmed by performing an immunofluorescence assay (IFA) with a virus specific antibody. Furthermore, they underwent two blind passages with extended incubation to confirm that the cell line did not support growth of the virus. All infected cell lines were subjected to three total serial passages with the second and third passage utilizing a 1:100 dilution of virus inoculum in media rather than MOI. For a direct comparison of virus susceptible cell lines using MOI for passage 1, virus titration was performed RD cell line (Table 1).

The cells lines A549, MRC-5 and HEK-293 T/17 support growth of both EV-D68 viral isolates. These results are comparable to the same viral isolates grown in RD cells. HEK-293 cells supported growth of US/MO/14 18947 but showed reduced virus fitness for the three passages tested and did not support growth of the US/KY/14-18953 virus. CHO cells expressing the ICAM-1 receptor was not susceptible to the two isolates used in the cell screening assessments.
 

*US/MO/14-18947 is available in the BEI Resources catalog as NR-49129 and US/KY/14-18953 as NR-49132

BEI Resources Screening of Cell Lines for EV-D68 Propagation in Serum Free Media
BEI Resources performed a second screen of cell lines under serum free conditions to assess the growth of EV-D68 . Four of the cell lines (MRC-5, A549 and HEK-293 T/17 and 293) were adapted to grow in serum free conditions by weaning serum and switching into chemically defined media with supplements . All the cell lines were grown in viral growth media (base media recommended for each cell line) supplemented with 2% FBS to serve as controls. An additional control included use of RD cells grown in base media with 2% serum. (see Table 2 for details)

Serum Free (SF) adapted cell lines were grown in appropriate growth media at 37°C and infected with the EV-D68 isolate US/MO/14-18947 at a MOI of 0.001. All cell lines were incubated at 33°C for three passages with each successive passage infected at MOI of 0.001. All control cell lines were similarly infected. At the end of each passage virus from all cell lines were titrated (see Table 2). Note that viral titers were determined by a standard assay using RD cells.
 

Infection and viral production of the EV-D68 US/MO/14-18947 virus isolate was successful over the course of three passages in serum free conditions for three cell lines, A549, MRC-5, and HEK-293 T/17, however HEK-293 did not support the growth of the virus. The CPE for HEK-293 T/17 in SF adapted cells is difficult to discern as the cells lose anchorage dependence. As a result, confirmation of viral infection in HEK-293 T/17 SF adapted cells requires IFA.

Summary of BEI Resources Cell Screening for EV-D68 Propagation
Using two EV-D68 isolates, it was observed that two cell lines A549 and MRC-5 successfully supported virus growth after adaptation to serum-free conditions for use in downstream vaccine developmental needs. Both the cell lines were found to be robust and tolerated the serum weaning process while maintaining their morphology and viability.

For guidance and protocols on serum free adaptation of cell lines A549, MRC-5, HEK-293 and HEK-293 T/17, please visit our Knowledge Base.

For information on the availability of virus isolates grown in serum free A549 adapted cells, please email Contact@BEIResources.org.
 

Coming Soon - Available in Spring of 2020
NR-51996        Enterovirus D type 68, USA/2018-23087
NR-51997        Enterovirus D type 68, USA/2018-23088
NR-51998        Enterovirus D type 68, USA/2018-23089
NR-51999        Enterovirus A type 71, USA/WA/2016-19522
NR-52000        Enterovirus A type 71, USA/2018-23092
NR-51844        Enterovirus D type 68, USA/MO-18949 mouse-adapted

The following isolates obtained from AFM cases will be available in Summer of 2020
Enterovirus D68, USA/2018-23201
Enterovirus D68, USA/2018-23263
Enterovirus D68, USA/2018-23206
Enterovirus D68, USA/2018-23209
Enterovirus D68, USA/2018-23216

Chagas’ disease caused by the protozoan parasite Trypanosoma cruzi (T. cruzi) is widespread in Central and South America infecting an estimated 12 to 14 million people, with infection often leading to chronic myocarditis resulting in high morbidity and mortality. In addition to our catalog of T. cruzi parasites and triatomine vectors, BEI Resources now offers monoclonal antibodies raised against parasite stage-specific surface antigens, which play important roles during infection. These antigens include the trypomastigote-specific antigen Ssp-1 (BEI Resources NR-50891) and the amastigote-specific surface antigen Ssp-4 (BEI Resources NR-50892). Studies have shown the presence of Ssp-4 in tissue culture supernatants of T. cruzi-infected cells and the presence of anti-Ssp4 antibodies in sera from chagasic patients. These monoclonal antibodies were generously contributed by Dr. Norma Andrews, University of Maryland.  Dr. Andrews generated these monoclonal antibodies while at the laboratory of Dr. Ruth Nussenzweig, New York University.
Image:  Immunofluorescence staining of amastigotes of Trypanosoma cruzi, strain TcVT-1 (BEI Resources NR-36630) with Monoclonal Anti-Trypanosoma cruzi, NR-50892. A, Light microscopy image of T. cruzi-infected kidney epithelial cells (ATCC^® CCL-26™). B, Immunostaining of intracellular amastigotes with NR-50892 labeled with a FITC-conjugated rabbit anti-mouse antibody. Host cell and parasite nuclei are stained with DAPI.

References:

1. Andrews, N. W., et al. “Stage-Specific Surface Antigens Expressed during the Morphogenesis of Vertebrate Forms of Trypanosoma cruzi.”  Exp. Parasitol. 64 (1987):  474-484.  PubMed:  3315736.
2. Andrews, N. W., et al. “Developmentally Regulated, Phospholipase C-Mediated Release of the Major Surface Glycoprotein of Amastigotes of Trypanosoma cruzi.”  167 (1988):  300-314.  PubMed:  3279152.

Enterobacter cloacae is part of the normal human flora and not considered a primary pathogen. Unfortunately, there is increasing incidence of nosocomial infections with E. cloacae, which frequently involve intravenous and other medical and hospital devices as well as medical solutions and disinfectants used routinely in hospitals and patient care facilities. The situation is further complicated by the ability of these bacteria to acquire resistance to antibiotics, notably carbapenems. BEI Resources has obtained a set of 15 isolates of the E. cloacae complex with defined susceptibility patterns against 16 antibiotics. This valuable set is now available to aid your studies on carbapenem-resistant Enterobacteriaceae (CRE).

Mayaro virus (MAYV) is a New World alphavirus and the etiologic agent of Mayaro fever, an acute febrile illness sometimes accompanied by severe and persistent arthritis similar to Chikungunya fever. Its transmission cycle occurs mainly through mosquito vectors, especially those of the genus Haemagogus, but Aedes spp. mosquitoes may also be competent vectors. The enzootic transmission cycle of MAYV is not fully understood, but the occurrence of relatively large outbreaks of Mayaro fever and the competence of Aedes mosquitoes for the transmission of MAYV suggest the potential for an urban human-mosquito-human transmission cycle to emerge. MAYV was first isolated in Trinidad in 1954, with sporadic outbreaks of Mayaro fever in Bolivia, Brazil, and other regions throughout Central and South America. Recently, MAYV was found in a DENV co-infected patient in Haiti¹, the first report of MAYV in the Caribbean nation, underscoring the need for MAYV inclusion in surveillance activities in these regions in addition to Dengue, Chikungunya, and Zika viruses.

Una virus (UNAV) is the closest genetic relative of MAYV that also causes a similar febrile illness. UNAV was first identified in northern Brazil in 1959. Serosurveys have identified antibodies against UNAV in birds, horses, and humans; however, the extent of viral distribution and human disease risk is unknown.

References:1. eid2211.161015

Plasmid maintenance by bacteria can be unpredictable without selective pressure. This is of particular concern during in vivo studies. To circumvent this in Staphylococcus species, the Bose Lab at The University of Kansas Medical Center has provided plasmids to BEI Resources that remain stable inStaphylococcus cells without the requirement of antibiotics during both in vitro and in vivo experiments¹. These E. coli-S. aureus shuttle vectors are based on the LAC-p01 plasmid.

Plasmid pKK22 (Accession KX085042) is designed to be used with S. aureus USA300 strains that contain LAC-p01 and will render the strains isogenic. Plasmid pKK30 (Accession KX085043) is a variant of pKK22, in which the predicted open reading frames (ORFs) that are not needed for plasmid maintenance have been deleted, and is intended for use inStaphylococcus cells that do not contain LAC-p01. Both plasmids contain a single trimethoprim resistance cassette that is functional in both E. coliand Staphylococcus. In addition, they contain the E. coli R6Kγ origin of replication and require pir+ cells for replication. DH5αλpir and the pir+dam- dcm- strain GM2163λpir are provided as a host strains, courtesy of Dr. Eric Stabb (University of Georgia)². These plasmids and host strains are now supplied individually or as a kit through BEI Resources.

References:

1. Krute, C. N., K. K. Krausz, M. A. Markiewicz, J. A. Joyner, S. Pokhrel, P. R. Hall, and J. L. Bose. 2016. "Generation of a Stable Plasmid for in vitro and in vivostudies of Staphylococcus." Applied and Environmental Microbiology 82:6859-6869. PMID 27637878

2. Dunn A. K., M. O. Martin, and E. V. Stabb. 2005. "Characterization of pES213, a Small Mobilizable Plasmid from Vibrio fischeri." Plasmid 54:114-134. PMID: 16122560

Clostridium difficile research is easier with strains from BEI Resources

For the benefit of researchers requiring nucleic acids from pathogens, BEI Resources offer more than 1,000 nucleic acids derived from pathogens. These reagents can be used at lower containment levels for molecular studies; to ensure their biosafety, the preparations have been safety tested for the absence of residual live organisms. Please check our website to see the wide variety viral nucleic acids extracted from various BSL-2 through BSL-4 pathogens. Notable new additions to this category of reagents include Genomic RNA from Enterovirus D68 and human metapneumovirus.

Whooping cough is a disease caused by bacteria from the genus Bordetella. Currently under widespread resurgence, whooping cough ranks globally among the 10 leading causes of childhood mortality. BEI Resources offers several isolates of Bordetella pertussis, B. bronchiseptica, and B. holmesii, along with toxins, nucleic acids, and proteins for Bordetella research. To see the full list of Bordetella reagents and strains currently available from BEI resources, please click here

Image:  Bordetella holmesii NR-43499 grown on Bordet Gengou media

Toxoplasma gondii is an obligate intracellular protozoan parasite of the phylum Apicomplexa that is the causal agent of toxoplasmosis. BEI Resources houses a comprehensive assortment of T. gondii cultures that include GFP-expressing strains; reference genome strains; genetic crosses between type strains I, II, and III; and strains used as models for parasite transmission and cyst formation. For a complete list of our Toxoplasma catalog, please contact us at Contact@BEIResources.org.

¹ Available soon. Send inquiries to Contact@BEIResources.org for availability.

BEI Resources offers 42 distinct Escherichia coli-Staphylococcus cassette-based shuttle vectors that provide all the tools you need to complete your research. These shuttle vectors are deposited as part of the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) reagents. Choose from staphylococcal low-copy-number, high-copynumber, thermosensitive, and theta-replicating plasmids. Select from erythromycin, tetracycline, chloramphenicol, kanamycin, or spectinomycin selectable markers in Staphylococcus, and ampicillin, erythromycin, kanamycin, and chloramphenicol resistance markers in E. coli. The modular design of the plasmid vector system offers flexibility and variety for expression analysis and provides the opportunity to address questions about gene dosage, complementation, and cis-trans effects. The shuttle vector system provides effective tools for studying gene regulation of staphylococci among ecosystems.

For further published details on these plasmids, please see Charpentier et al. Appl

Environ Microbiol 70(10): 6076-6085, 2004

Image:  NR-46158. Staphylococcus aureus strain 4221 containing shuttle vector pCN57, grown on TSA + 10 μg/ml erythromycin

.

We have a number of expression plasmids for various Filoviral proteins for Zaire Ebolavirus and Marburgvirus. Many of the proteins have been tagged with HA or FLAG. Continue to check our catalog for new plasmid additions, such as those expressing GP, NP, VP24, VP30, VP35, and VP40 in the next few months for a complete list.

Registration for the BEI Resources program can be found at this link below. NARSA Strain requestors will need to register for Level 2 for continued access to the NARSA Strains. ** Please note if you are an existing NARSA registrant, BEI Resources will contact you after the Annual Meeting with specific registration instructions and paperwork to facilitate your registration.

http://www.beiresources.org/Register.aspx

Once registered with BEI Resources, researchers will have access to the full BEI Resources catalog (within the respective Biosafety Level). The catalog has over 12,000 research reagents representing more than 400 Genus and Species focusing on NIAID's Category A, B and C priority pathogen list and Emerging Infections.

Once registered with BEI Resources, ALL investigators will receive FREE shipping and handling on orders placed through BEI Resources.

Please feel free to contact BEI Resources by email: contact@beiresources.org or by phone: Toll-free telephone number: (800) 359-7370 (8:30 AM to 4:30 PM Eastern Time) with any questions or concerns.

General Information about the Schistosoma spp. Life Cycle Training Course

Biomedical Research Institute

12111 Parklawn Drive Rockville, MD.

May 21-23, 2014

This course is designed to acquaint investigators working in the field of schistosomiasis with basic techniques and strategies for maintaining Schistosoma mansoni, S. haematobium, and S. japonicum in the laboratory, and it offers directions into making one’s research more productive.  Among the topics covered will be procedures for setting up and maintaining the complete S. mansoni/Biomphalaria glabrata life cycle in the research laboratory, an overview of schistosomiasis, the pathology of the disease, collection of adult worms and eggs from tissues, exposure of snails to miracidia, shedding snails, exposure of mice and hamsters to cercariae, and an examination of all the intramolluscan life stages.  Hands-on exercises relating to some of these topics will also be presented (ex. perfusion of mice, exposing mice/hamsters, identification of sporocysts in snails).  Since we first began offering this basic course, over 120 scientists, technicians and students have benefited from completion of the course, and have expanded their own research agendas once back in their own laboratories.

The workshop incorporates aspects of all three Schistosoma spp. life cycles.  Attendees will be exposed to aspects of maintaining S. japonicum and S. haematobium life cycles that include general snails maintenance, collection of cercariae from infected snails, and exposing mice/hamsters.  It is our hope that incorporating the other two life cycles will encourage interest in maintaining these species in attendees’ laboratories.  The three-day course will also include a lecture on NIH-NIAID parasitology and grant programs. 

We anticipate that attendees will come away with a greater appreciation of the basic biology of Schistosoma spp. parasites, greater confidence in maintaining life cycles, and they will learn strategies for optimizing life cycles in their home laboratories.  Time will be available to ask questions about life cycle maintenance and other aspects of schistosomiasis research. There is no fee for the course.  Attendees are responsible for travel and lodging expenses, but travel assistance may be available. If you have any questions about the course, please contact me at mtucker@afbr-bri.com or (301) 881-3300 x31, or Mitzi Sereno at msereno@afbr-bri.com or (301) 881-3300 x39.

BEI Resources has the MERS-CoV virus (strain EMC/2012) available for distribution to qualified laboratories.  This virus will require a BEI Level 3 registration.  Middle East Respiratory Syndrome (MERS) is viral respiratory illness first reported in Saudi Arabia in 2012. It is caused by a coronavirus called MERS-CoV. Most people who have been confirmed to have MERS-CoV infection developed severe acute respiratory illness. They had fever, cough, and shortness of breath. About half of these people died.

The catalog number for the MERS-CoV virus is NR-44260. You must be logged in with a valid BEI Level 3 Account to place an order. Please email our customer service department if you have any questions about obtaining the MERS-CoV virus.

Information Regarding the 2019 SARS-CoV-2

FAQs 

Materials Available

Coming Soon

Forms
 

BEI Resources currently does not have a shortage or a delay in shipping virus and RNA to qualified laboratories. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations and orders.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations and a 24-48 hour turn-around time on approved orders.  Please indicate SARS-CoV-2 in your scope of use in your registration paperwork.  Please contact BEI Resources at contact@beiresources.org for questions.

BEI Resources is working to accession strains of the 2019 novel coronavirus, recently named SARS-CoV-2, identified as the causative agent of an outbreak of viral pneumonia, COVID-19. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

We anticipate a large number of requests from the research community for these reagents, and we cannot guarantee how quickly stock will become available. Please continue checking for updates.

If you wish to transfer SARS-CoV-2 materials, please use the guidance provided in the Emergency Use Simple Letter Agreement.

The BEI Resources catalog offers additional coronavirus materials ready and available for distribution to qualified laboratories.

For access to BEI Resources full catalog, click here.

Frequently Asked Questions 

1. Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?
2. How long will it take to get SARS-CoV-2 materials?
3. How long will it take to process my registration to receive SARS-CoV-2 materials?
4. Who is qualified to receive SARS-CoV-2 materials?
5. What level of registration do I need to receive SARS-CoV-2 materials?
6. What is the Emergency Use Simple Letter Agreement (EUSLA)?
7. Is the Emergency Use Simple Letter Agreement required if only ordering the RNA?
8. If I have questions regarding SARS-CoV-2 materials, who do I contact?
9. How much do SARS-CoV-2 materials cost?
10. Are COVID-19 patient samples currently available from BEI Resources?
11. How do I obtain test kits for COVID-19?
12. Why is the SARS-CoV-2 RNA (NR-52285) only distributed to facilities which have BSL-2 laboratories?
13. Can I transfer SARS-CoV-2 materials?
14. Can I commercialize SARS COV-2 materials?
15. Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?
16. Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?
17. How do I find out about SARS-CoV-2 products coming soon?

Question: Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?

Answer: No, BEI Resources currently does not have a shortage or a delay in shipping virus and RNA to qualified laboratories. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.

Back to Questions

Question: How long will it take to get SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing all SARS-CoV-2 shipments.  Shipments are generally being made within 24-48 hours of completed requests.  If permits are required, these timelines are dependent on obtaining those permits.  Please contact us at contact@beiresources.org for any shipment questions.

Back to Questions

Question: How long will it take to process my registration to receive SARS-CoV-2 materials?

Answer: BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations.  We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations.  Please indicate SARS-CoV-2 in your scope of use.  Please contact BEI Resources at contact@beiresources.org for questions.

Back to Questions

Question: Who is qualified to receive SARS-CoV-2 materials?

Answer: Registration with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources reagents are shared with registered individuals and organizations doing research on Emerging Infections and other relevant areas of interest related to Microbiology. To register you must be affiliated with a public, private, academic, non-profit or for-profit institution. Registrants must demonstrate they work in an established institution with facilities and safety programs appropriate for the Level of registration requested.

Back to Questions

Question: What level of registration do I need to receive SARS-CoV-2 materials?

Answer: Each product on the BEI Resources website lists a BEI Resources level of registration.  Interested researchers will need to ensure they are registered at the appropriate level to receive materials.  Please click here for registration instructions.  If you need to upgrade your registration to a higher level, please click here for instructions.

Back to Questions

Question: What is the Emergency Use Simple Letter Agreement (EUSLA)?

Answer: The Emergency Use Simple Letter Agreement outlines the terms in which SARS-CoV-2 materials are being provided.  In light of the emergence of the novel coronavirus, 2019-SARS-CoV-2, and urgent need to mitigate the pathogen’s spread, the EUSLA was instituted for the provision of these materials under the terms outlined in the agreement. The EUSLA is not negotiable.

Back to Questions

Question: Is the Emergency Use Simple Letter Agreement required if only ordering the genomic RNA?

Answer: Yes, the EUSLA is required by Health and Human Services even if you are only ordering the genomic RNA. Please note that the signature of an authorized official (biosafety officer) to certify that your facility can safely handle the material is only required for receipt of the virus.

Back to Questions

Question: If I have questions regarding SARS-CoV-2 materials, who do I contact?

Answer: Please contact BEI Resources at contact@beiresources.org for any questions regarding SARS-CoV-2 materials.

Back to Questions

Question: How much do SARS-CoV-2 materials cost?

Answer: All BEI Resources reagents, including SARS-CoV-2 materials, are provided world-wide at no cost. While there is no cost for the reagents themselves, additional shipping and handling charges may apply and will display in the shopping cart if applicable.

Back to Questions

Question: Are COVID-19 patient samples currently available from BEI Resources?

Answer: We understand how important it is to share patient samples, including sera, nasal swabs and PBMCs, with researchers, especially during an outbreak. We do not currently have a timeline for when these samples will become available. When ready, we anticipate a large number of requests from the research community for patient samples related to the pandemic, and we do not yet know what quantity of samples will be available. Please contact our email box at contact@beiresources.org with your request and we will forward your request to NIAID so that they can prioritize those samples once available.

Back to Questions

Question: How do I obtain test kits for COVID-19?

Answer: Test kits are not distributed through BEI Resources. The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel was developed for qualified domestic public health laboratories to detect SARS-CoV-2. The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on February 4, 2020, to enable emergency use of the test kit in the United States. CDC has produced EUA and Research Use Only (RUO) test kits that are now available to order by domestic and international public health partners through IRR (www.internationalreagentresource.org). Please contact the International Reagent Resources program for more information – contact@internationalreagentresource.org.

Back to Questions

Question: Why is the SARS-CoV-2 RNA (NR-52285) only distributed to facilities which have BSL-2 laboratories?

Answer: CDC guidelines state that molecular analysis of extracted nucleic acid preparations should be performed in BSL-2 facility using standard BSL-2 work practices. The CDC guidelines can be found in the following link: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html

Back to Questions

Question: Can I transfer SARS-CoV-2 materials?

Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources and excludes any derivatives made by the recipient. The SARS-CoV-2 materials received under the EUSLA, and as defined above, may be further distributed to other entities for legitimate purposes required to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of SARS-CoV-2 and under terms no more restrictive than the Emergency Use Simple Letter Agreement (EUSLA). To ensure compliance with this, copies of the EUSLA or MTAs recording all further transfers must be sent back to contact@beiresources.org. This requirement must also be incorporated for further transfers. The recipient and provider agree to transfer, use, manage, and control the SARS-CoV-2 materials in compliance with all applicable laws and regulations. When these commodities, technology or software are exported from the United States, the recipient agrees to comply with the Export Administration Regulations. Diversion contrary to U.S. law is prohibited. Any new materials made by you that are not the original material or unmodified progeny are excluded from this requirement and you are free to share and commercialize those as your materials.

Back to Questions

Question: Can I commercialize SARS COV-2 materials? 

Answer: SARS-CoV-2 materials provided by BEI Resources under the EUSLA are made available for any legitimate purpose, including commercial purposes as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2.  Any further transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA, documented as described above and you must notify BEI Resources of each subsequent transfer.  Any new materials made by you that are not the original material or unmodified progeny are excluded from this requirement and you are free to share and commercialize those as your materials. 

Back to Questions

Question: Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?

Answer: The BEI Resources website provides a link on each product detail page for applicable permits. Please check the individual product detail pages for this information. SARS-CoV-2 isolates which originate from the United States do not require a CDC permit for domestic transfer. SARS-CoV-2 isolates which are deposited into BEI Resources outside of the USA, will be brought into the repository under a CDC permit, and will require a CDC permit for transfer.

Back to Questions 

Question: Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?

Answer: All Product Sheets and Certificates of Analysis can be found on the BEI Resources website. Perform a search for the product, and you will find the documentation. Any product listed as requiring a BSL-3 facility, will require login first to view the documentation. Only BEI Level 3 registrants will have access to view and download products requiring BSL-3 facilities.

Back to Questions 

Question: How do I find out about SARS-CoV-2 products coming soon?

Answer: BEI Resources will list the status of SARS-CoV-2 products coming soon in the table above titled Coming Soon and Expected Availability.

Back to Questions 

Forms

Emergency Use Simple Letter Agreement (EUSLA)

Back to the top

The much awaited H7N9 Influenza virus is now available for your research needs. NR-44078 is a 6:2 reassortant virus produced using plasmid-based reverse genetics to contain the hemagglutinin and neuraminidase genes from A/Shanghai/1/2013 (H7N9) and internal genes from A/Puerto Rico/8/1934 (H1N1).

Click here to see all H7N9 reagents.

As of Wednesday, August 20th we have updated the BEI Resources and MR4 websites to further optimize your online experience; making it easier, more accessible, and hopefully a bit more pleasurable to access your desired BEI and MR4 reagents. We have rolled out a new redesigned website that we anticipate will provide a more user-friendly navigation and shopping cart experience, easier searching and reading throughout the site, and an optimal viewing experience from essentially any web accessible platform whether it is desktop, laptop, mobile phone, or tablet.

This Responsive Web Design approach suggests that design and development should respond to the user’s behavior and environment based on screen size, platform, and orientation. As more and more of our customers in the scientific community are switching to the duality of laptops and mobile devices to conduct and support their research efforts, we at BEI Resources, would like to let our customers know… We’ve heard you… and would like to thank you for your continued feedback.

This redesigned website has been engineered to automatically respond to user preferences; switching to accommodate for resolution, image size and the scripting capabilities as dictated by the device being used. We can now make images and layouts more flexible. With this design, we have essentially eliminated the need to make individual adjustments in design and development for each new mobile device produced and made available on the market.

While Responsive Design is not a complete solution, we believe this solution provides more options for our users and a more optimal online experience overall when accessing the BEI Resources and MR4 sites; from any website accessible device; mobile or otherwise.

So feel free to access the BEI Resources and MR4 sites while in the office, lab, or on-the-go with your mobile device. An option to provide feedback is available through our Online User Feedback form, provided at the completion of your online order. Tell us what you think; we look forward to hearing from you.

At MR4 and BEI Resources, “We take care of the details - so you can focus on your research.”  

We have available for the first time in the BEI Resources catalog, two SARS Coronaviruses (SARS-CoV) derived from the Urbani strain. NR-18925 is produced from a recombinant infectious clone, icSARS-CoV. NR-15418 is the mouse-adapted strain, Urbani v2163, developed by Dr. Barnard as a lethal model for evaluating antiviral agents (PubMed:19853271). To view a complete listing of all coronaviruses in the catalog, click here.

BEI Resources announces the addition of Sand Flies, Reduviids and Ticks for the research community.

CDC recommends handling naïve ticks from these species at ABSL2 containment in appropriate barrier protected facilities; pathogen research may require elevated ABSL containment. Check the BEI Vector Resources page for a list of other vectors and related reagents available through BEI Resources.

Chikungunya Viruses - Additional Strains Available

BEI Resources announces the addition of two novel BSL3 strains of Chikungunya virus (CHIKV), R-91142 and 182/25, to the catalog of available items. CHIKV is a mosquito-borne alphavirus that is mainly associated with acute febrile illness. Strains R-91142 and 182/25 CHIKV are of Asian origin. Strain 182/25 is the recently developed vaccine candidate and the only CHIKV strain to be tested in humans. Coming soon to the BEI catalogue is the CHIKV African prototype strain, S-27.

Recent acquisitions in BEI Resources aim to contribute to research focused on understanding the mechanisms of disease and the development of novel therapeutic drugs for Trypanosome research. Such acquisitions include SSGCID clones, proteins and reference parasite strains used in genome and virulence studies. For more information on the availability of these materials please contact BEI Resources customer service.

BEI Resources is working to expand the fungal resources so that researchers have a broader range of organisms and reagents for their work.  BEI Resources currently has eight genus and species represented with several more currently going through the production pipeline.  BEI Resources is actively encouraging depositors with medically relevant strains to deposit into the repository. If you are interested in depositing, please click here.

The ISO Guide 34 accreditation by the American Association for Laboratory Accreditation (A2LA) builds upon the earlier certification for compliance with the ISO 9001:2000 standard for quality management systems received by ATCC in 2007. Biological reference materials produced under an ISO Guide 34-accredited process have confirmed identity, well-defined characteristics and an established chain of custody — qualities essential to their effectiveness as biological standards in research and development.

BEI Resources is pleased to announce a new and improved website!  We heard your feedback concerning difficult searches and long checkout times…and, we invite you to explore and discover our new dynamic search package, state-of-the-art shopping cart experience and enhanced product information pages for your items on interest.

Our new search engine provides the community with a user friendly interface in which to research, search, and order reagents. We will now be using the same search and navigation features of many of the world's largest internet sites. Some of the major search features include dynamic filter searching, Intuitive Auto-Complete Text Searches, Suggested Search Terms, Dynamic Clustering and multiple sorting parameters for result sets.

Your ordering experience is also vastly improved with our new Web Services E-Commerce software.  No more waiting for your items to load to the shopping cart; with the new software, your checkout is fast and reliable. Look for all these updates today!

The agent of bubonic plague Yersinia pestisis a NIAID Category A Priority Pathogen and likely biothreat. In support of research and product development in this area BEI Resources released a Yersinia pestis Plasmid Detection Kit (NR-9562) in April 2008.   

This assay allows the researcher to quickly identify the presence of plasmid-encoded virulence factors pPCP1, pMT1 and pCD1 and is designed to be used for characterization purposes in conjunction with standard microbiological techniques.

The assay consists of primer sets designed to specifically detect the pPCP1, pMT1 and pCD1 plasmids using standard polymerase chain reactions and includes a species-specific positive control primer set and internal positive control template.

PCR amplification of genomic DNA from Yersinia pestis displaying a pPCP1+, pMT1+, pCD1– profile (lanes 2-4 respectively). Lanes 5 and 6 are the Yersinia pestis and internal positive controls. Lane 7 is a non-template control."

Panel A. Growth of Yersinia pestis on Congo Red media showing red/orange colonies typical of pgm+ organisms. Organisms that are confirmed pgm+ and pCD1+ are considered Select Agents.

Panel B. Bacteria lacking pgm showing distinctive variations in colony morphology and reduced coloring on Congo Red media as compared to pgm+ organisms.

For technical questions about these products or to learn more, please contact our Technical Services Department.